With precision medicine as an investment theme and global R&D level as a benchmark, we aim to deliver the emerging market demand in China by focusing on Biotechnology, New Drug R&D, Emerging Medical Service and Advanced Medical Devices. We primarily focus on early- to mid stage projects, but also consider other stages. SC manages three healthcare funds and covers more than 80 projects.
Gusen Pharmaceutical is China's leading company devoted to the development and production of soft mist inhaler, and the only enterprise that is listed among the "national science and technology major projects" in soft mist inhaler, with high-end reagent technology as the cornerstone.
We aim for a fine blueprint of lifestyle for the next generation of consumers, by searching for the business model and product innovation from the up, middle and down stream of the industry. SC manages three consumer-driven innovation funds and covers more than 70 projects.
We pay close attention to the technological breakthroughs of China's leading scientific research team, and mainly focus on AI and Big Data, Advanced Manufacturing, the New Generation of IT and New Materials. We give priority to projects headquartered in the Greater Bay Area with Shenzhen as a center. SC manages one hardcore technology angel fund and covers more than 10 projects.
NavInfo (002405.SZ) is the pioneer in China's navigation map industry and develops "the brain of smart vehicles" through such core technologies as self-driving map, high-precision positioning, cloud service platform as well as automotive-grade chips applicable to ADAS and self-driving to empower smart mobility.
The world's enterprise-class smart service platform of data analysis and decision, committed to supporting the mid- and large-sized enterprises with highly complicated knowledge and management in their digital transformation by leveraging data analysis and digging and cognitive smart technology.